Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...
The MarketWatch News Department was not involved in the creation of this content. Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback